Trial finds drug reteplase may be another option for stroke thrombolysis
UC expert comments on study to TCT MD
The University of Cincinnati's Pooja Khatri commented to TCTMD on the RAISE trial that found drug reteplase may be a safe and effective option to treat acute ischemic stroke.
Like drugs tenecteplase and alteplase, reteplase is a clot-busting medication that was administered to patients within 4.5 hours of stroke onset during the trial. The drug was found to lead to a higher rate of excellent functional outcome compared with standard alteplase with no significant increase in symptomatic intracranial hemorrhage, other bleeding outcomes or death.
The trial “raises the possibility of another intravenous thrombolytic drug that we could use to treat acute stroke patients,” said Khatri, MD, professor, vice chair of research and division chief in the Department of Neurology & Rehabilitation Medicine at UC's College of Medicine and associate director of the UC Gardner Neuroscience Institute, noting that this is the first phase III trial to address the topic.
“It opens some doors, but we need more data to know if this is going to have a role in our armamentarium as part of our standard of care in the long run,” Khatri added.
Featured photo at top of illustration of brain with stroke symptoms. Photo/PeterSchreiber.media/iStock.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.